FDA Inspection
Niagara Pharmaceuticals IncNiagara Pharmaceuticals Inc – FDA Inspection, Feb 7, 2020
Record Details
This FDA Inspection record concerns Niagara Pharmaceuticals Inc, with an inspection on February 7, 2020, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Niagara Pharmaceuticals Inc
- Inspection Date
- February 7, 2020
- Product Type
- Drugs
View Company Profile
ID · dbc973f2-edee-4f9c-a795-0718e8a091a2
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1117142
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
2- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.192Investigations of discrepancies, failures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Niagara Pharmaceuticals Inc
5| Date | Classification | Office | Project area |
|---|---|---|---|
| April 25, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 18, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 16, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 14, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 8, 2010 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Niagara Pharmaceuticals Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.